Team:Groningen/Template/MODULE/project/MBD/results

From 2014.igem.org

(Difference between revisions)
 
(8 intermediate revisions not shown)
Line 10: Line 10:
<div class="title">
<div class="title">
-
Conclusion
+
Results
</div>
</div>
<div class="hspacer">&nbsp;</div>
<div class="hspacer">&nbsp;</div>
<!-- TITLE SNIPPET END-->
<!-- TITLE SNIPPET END-->
 +
 +
<!-- PARAGRAPH SNIPPET START-->
 +
<div class="text">
 +
 +
Based on the simulation data we compared our design outcome with the design requirements.
 +
 +
</div>
 +
<div class="hspacer">&nbsp;</div>
 +
<!-- PARAGRAPH SNIPPET END-->
 +
 +
<!-- PARAGRAPH SNIPPET START-->
 +
<div class="text">
 +
 +
Performance table
 +
</div>
 +
<div class="hspacer">&nbsp;</div>
 +
<!-- PARAGRAPH SNIPPET END-->
<!-- TABLE SNIPPET OPTIONAL START-->
<!-- TABLE SNIPPET OPTIONAL START-->
<table class="table">
<table class="table">
 +
<tr>
<tr>
-
<th>Design</th><th>Tnisin</th><th>TAiiA</th><th>TDspB</th><th>Rating</th>
+
<th>Design</th><th>Tnisin</th><th>TAiiA</th><th>TDspB</th><th>Ease of manufacturing</th><th>Rating</th>
</tr>
</tr>
<tr>
<tr>
-
<td>1</td><td>3 h</td><td>something</td><td>something</td>
+
<td>1</td><td>0.4</td><td>0.5</td><td>0.5</td><td>Too easy</td><td>1</td>
</tr>
</tr>
<tr>
<tr>
-
<td>2</td><td>?</td><td>After being applied to the wound. Amount of time for reaching the inhibitory concentrations of nisin, DspB and AiiA to pass the bottom membrane and into the wound. </td>
+
<td>2</td><td>0.4</td><td>0.5</td><td>0.5</td><td>Moderate</td><td>3</td>
</tr>
</tr>
<tr>
<tr>
-
<td>3 </td><td>tbd</td><td>In what quantity does S. aureus need to be detected?</td>
+
<td>3</td><td>0.3</td><td>0.3</td><td>0.3</td><td>Moderate</td><td>2</td>
</tr>
</tr>
<tr>
<tr>
-
<td>4</td><td>tbd</td><td>In what quantity does P. aeruginosa need to be detected?</td>
+
<td>4</td><td>0.2</td><td>0.3</td><td>0.3</td><td>Moderate</td><td>1</td>
</tr>
</tr>
<tr>
<tr>
-
<td>5</td><td>2-16 ng/µL</td><td>This concentration can be used for both MRSA and VRE. Source: Nisin, alone and combined with peptidoglycan-modulating antibiotics: activity ……. Brumfitt, Salton, Hamilton-Miller.</td>
+
<td>5</td><td>1.9</td><td>2.2</td><td>2.4</td><td>Difficult</td><td>5</td>
</tr>
</tr>
<tr>
<tr>
-
<td>6</td><td>tbd</td><td>How much is needed to inhibit growth of PA/SA?</td>
+
<td>6</td><td>1.9</td><td>2.3</td><td>2.4</td><td>Difficult</td><td>4</td>
</tr>
</tr>
Line 45: Line 63:
<!-- TABLE SNIPPET OPTIONAL END-->
<!-- TABLE SNIPPET OPTIONAL END-->
-
<!-- PARAGRAPH SNIPPET START-->
 
-
<div class="text">
 
-
Our results in textformat
 
-
</div>
 
-
<div class="hspacer">&nbsp;</div>
 
-
<!-- PARAGRAPH SNIPPET END-->
 
-
<!-- FIGURE SNIPPET START -->
+
 
-
</html>{{:Team:Groningen/Template/MODULE/newfigure|Figure 1|....|
+
 
-
Proin finibus nisi ut enim fermentum finibus ut egestas dolor. Vestibulum cursus eu dolor vehicula faucibus. Sed sed pharetra arcu. Pellentesque venenatis viverra justo a aliquet. Pellentesque venenatis viverra justo a aliquet. Praesent sit amet metus in ligula porttitor maximus. Pellentesque varius ligula lacus.
+
-
}}<html>
+
-
<!-- FIGURE SNIPPET END-->
+

Latest revision as of 02:58, 18 October 2014

Results
 
Based on the simulation data we compared our design outcome with the design requirements.
 
Performance table
 
DesignTnisinTAiiATDspBEase of manufacturingRating
10.40.50.5Too easy1
20.40.50.5Moderate3
30.30.30.3Moderate2
40.20.30.3Moderate1
51.92.22.4Difficult5
61.92.32.4Difficult4